Insulin degludec + insulin aspart (Ryzodeg Penfill)
Insulin degludec + insulin aspart risk profile, scheduling, and guidance for claims professionals and care workers . Also known as Ryzodeg Penfill.
Insulin degludec + insulin aspart (brand names: Ryzodeg Penfill) is classified as Low risk (1 risk points) by AllMeds. It is a S4 medication under the TGA in Australia. Long-acting insulin combination with hypoglycemia risk requiring workplace safety consideration.
Key Takeaways
- TGA Schedule: S4 in Australia
- Risk level: Low (1 points)
- PBS listed: Subsidised under the Australian Pharmaceutical Benefits Scheme
Scheduling and Classification
| Jurisdiction | Classification | Status |
|---|---|---|
| Australia (TGA) | S4 | PBS listed |
Risk Profile
Long-acting insulin combination with hypoglycemia risk requiring workplace safety consideration.
Regulatory and Compliance Guidance
When Insulin degludec + insulin aspart appears on a claimant's medication list, claims professionals should assess whether the prescribing is appropriate for the compensable injury, whether the duration is within guidelines, and whether there are interactions with other medications on the claim.
Australia TGA / PBS / State Schemes
Classified as S4 under the Therapeutic Goods Administration (TGA).
Listed on the Pharmaceutical Benefits Scheme (PBS) for subsidised prescribing.
Need to assess this medication across your caseload?
Run a full risk assessment including Insulin degludec + insulin aspart interactions and compliance checks.
AllMeds gives you instant risk assessments, compliance checks, and automated letters for every medication on a claim.
Medical Disclaimer: This content is for informational purposes for claims professionals and care workers. It is not medical advice. Always consult a qualified healthcare professional for clinical decisions. Drug information is sourced from TGA, FDA, MHRA, PBS, NICE, and CDC databases and may not reflect the latest updates. AllMeds does not replace clinical judgement.